Bacterial infection
Drug research and approvals for bacterial infection: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 720 studies of bacterial infection are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 720
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 0
- The PRECISION Partners Platform (P3) StudyNCT07944183 · Not reported · Imperial College London · starts Jun 23, 2026
- A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6…NCT07947056 · Phase 3 · Tuberculosis Research Centre, India · starts Jun 6, 2026
- Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin DiseasesNCT07944196 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Apr 11, 2026
- Factors Associated With Positive Post-Treatment STI Tests and Sexual Knowledge, Attitudes, Behaviors and PracticesNCT07936214 · Not applicable · Centre Hospitalier de Martigues · starts Oct 29, 2026
- Topical Lactoferrin and Luliconazole, Alone or in Combination, for Tinea CorporisNCT07937020 · Not applicable · Kafrelsheikh University · starts Sep 1, 2026
- Typhoid Conjugate Vaccine Introduction in Madagascar (TyMA): Evaluation of the Real-World Effectiveness of the…NCT07930988 · Phase 4 · Rita Soares Barbosa Cardona · starts Jul 23, 2023
- Clinical Characteristics, Treatment, Diagnostic Findings, and Outcomes of Tuberculous Meningitis in Indonesia, 2022-2025NCT07929519 · Not reported · Ina-Respond · starts Sep 24, 2026
- EFFECTIVENESS OF A SCHOOL-CENTRED PRIMARY AND SECONDARY PREVENTION PROGRAM ON PREVALENCE OF LATENT RHEUMATIC HEART…NCT07927868 · Not reported · Centre for Infectious Disease Research in Zambia · starts Jan 14, 2025
- Oral Switch in Bloodstream Infections in Immunocompromised ChildrenNCT07923266 · Phase 4 · Copenhagen University Hospital, Rigshospitalet · starts Nov 9, 2026
How its trials ended
641 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 126 whose ending is known, 51% met their primary endpoint, 9% missed it and 40% stopped early.
- Completed, result not reported32651%
- Ongoing11017%
- Status unknown7912%
- Met its primary endpoint6410%
- Stopped: other or unclear284%
- Stopped: enrollment or feasibility142%
- Missed its primary endpoint112%
- Stopped: sponsor or business decision71%
- Stopped: lack of efficacy2<1%
| Jun 5, 1998 | Sulfamylon solutionFor use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts… | Mylan Laboratories, Inc. | Approved |
| Aug 19, 2019 | Neutralizing equine anti-Stx hyperimmune immunoglobulin…Treatment of Shiga-toxin producing bacterial infection as it relates to the prevention of hemolytic uremic syndrome | Inmunova SA | Designated |
| Oct 4, 2005 | Chimeric monoclonal antibodies, c-alphaStx2For treatment of shiga-toxin producing bacterial infection | Taro Pharmaceuticals Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA